{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:47:01Z","timestamp":1792590421645,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T00:00:00Z","timestamp":1753833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Prostate Cancer Prostatic Dis"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1038\/s41391-025-01005-3","type":"journal-article","created":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:53:46Z","timestamp":1753894426000},"page":"529-534","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prostate specific membrane antigen focal ablation imaging (PSMA-FAB)"],"prefix":"10.1038","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9732-1094","authenticated-orcid":false,"given":"Egesta","family":"Lopci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4411-3715","authenticated-orcid":false,"given":"Massimo","family":"Lazzeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Fasulo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Maffei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Paolo","family":"Avolio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Tallari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Moretto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovica","family":"Cella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Rodari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica Mrakic","family":"Sposta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7899-5736","authenticated-orcid":false,"given":"Paolo","family":"Casale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f2 Maria","family":"Buffi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Lughezzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,30]]},"reference":[{"key":"1005_CR1","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.eururo.2024.03.027","volume":"86","author":"P Cornford","year":"2024","unstructured":"Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Brunckhorst O, Darraugh J, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer-2024 update. part i: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2024;86:148\u201363.","journal-title":"Eur Urol"},{"key":"1005_CR2","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/s41391-023-00702-1","volume":"27","author":"J Javier-DesLoges","year":"2024","unstructured":"Javier-DesLoges J, Dall\u2019Era MA, Brisbane W, Chamie K, Washington SL 3rd, et al. The state of focal therapy in the treatment of prostate cancer: the university of California collaborative (UC-Squared) consensus statement. Prostate Cancer Prostatic Dis. 2024;27:579\u201381.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1005_CR3","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/bju.15004","volume":"125","author":"CE Lovegrove","year":"2020","unstructured":"Lovegrove CE, Peters M, Guillaumier S, Arya M, Afzal N, Dudderidge T, et al. Evaluation of functional outcomes after a second focal high-intensity focused ultrasonography (HIFU) procedure in men with primary localized, non-metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry. BJU Int. 2020;125:853\u201360.","journal-title":"BJU Int"},{"key":"1005_CR4","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.eururo.2018.06.006","volume":"74","author":"S Guillaumier","year":"2018","unstructured":"Guillaumier S, Peters M, Arya M, Afzal N, Charman S, Dudderidge T, et al. A multicentre study of 5-year outcomes following focal therapy in treating clinically significant nonmetastatic prostate cancer. Eur Urol. 2018;74:422\u20139.","journal-title":"Eur Urol"},{"key":"1005_CR5","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/bju.14710","volume":"124","author":"A Stabile","year":"2019","unstructured":"Stabile A, Orczyk C, Hosking-Jervis F, Giganti F, Arya M, Hindley RG, et al. Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer. BJU Int. 2019;124:431\u201340.","journal-title":"BJU Int"},{"key":"1005_CR6","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1038\/s41391-020-00315-y","volume":"24","author":"TT Shah","year":"2021","unstructured":"Shah TT, Reddy D, Peters M, Ball D, Kim NH, Gomez EG, et al. Focal therapy compared to radical prostatectomy for non-metastatic prostate cancer: a propensity score-matched study. Prostate Cancer Prostatic Dis. 2021;24:567\u201374.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1005_CR7","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41391-022-00501-0","volume":"26","author":"JR Heard","year":"2023","unstructured":"Heard JR, Naser-Tavakolian A, Nazmifar M, Ahdoot M. Focal prostate cancer therapy in the era of multiparametric MRI: a review of options and outcomes. Prostate Cancer Prostatic Dis. 2023;26:218\u201327.","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"1005_CR8","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(16)32401-1","volume":"389","author":"HU Ahmed","year":"2017","unstructured":"Ahmed HU, El-Shater Bosaily A, Brown LC, Gabe R, Kaplan R, Parmar MK, et al. PROMIS study group. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389:815\u201322.","journal-title":"Lancet"},{"key":"1005_CR9","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1056\/NEJMoa1801993","volume":"378","author":"V Kasivisvanathan","year":"2018","unstructured":"Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, et al. PRECISION Study Group Collaborators. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018;378:1767\u201377.","journal-title":"N Engl J Med"},{"key":"1005_CR10","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.euo.2020.12.004","volume":"4","author":"E Mazzone","year":"2021","unstructured":"Mazzone E, Stabile A, Pellegrino F, Basile G, Cignoli D, Cirulli GO, et al. Positive predictive value of prostate imaging reporting and data system version 2 for the detection of clinically significant prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol. 2021;4:697\u2013713.","journal-title":"Eur Urol Oncol"},{"key":"1005_CR11","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","volume":"76","author":"B Turkbey","year":"2019","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, et al. Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol. 2019;76:340\u201351.","journal-title":"Eur Urol"},{"key":"1005_CR12","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1148\/radiol.2020190646","volume":"296","author":"AC Westphalen","year":"2020","unstructured":"Westphalen AC, McCulloch CE, Anaokar JM, Arora S, Barashi NS, Barentsz JO, et al. Variability of the positive predictive value of PI-RADS for Prostate MRI across 26 centers: experience of the society of abdominal radiology prostate cancer disease-focused panel. Radiology. 2020;296:76\u201384.","journal-title":"Radiology"},{"key":"1005_CR13","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.euo.2020.06.007","volume":"3","author":"F Giganti","year":"2020","unstructured":"Giganti F, Allen C, Emberton M, Moore CM, Kasivisvanathan V. PRECISION study group. Prostate Imaging Quality (PI-QUAL): A New Quality Control Scoring System for Multiparametric Magnetic Resonance Imaging of the Prostate from the PRECISION trial. Eur Urol Oncol. 2020;3:615\u20139.","journal-title":"Eur Urol Oncol"},{"key":"1005_CR14","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.euo.2023.04.007","volume":"6","author":"F Giganti","year":"2023","unstructured":"Giganti F, Dickinson L, Orczyk C, Haider A, Freeman A, Emberton M, et al. Prostate imaging after focal ablation (PI-FAB): a proposal for a scoring system for multiparametric MRI of the prostate after focal therapy. Eur Urol Oncol. 2023;6:629\u201334.","journal-title":"Eur Urol Oncol"},{"key":"1005_CR15","doi-asserted-by":"publisher","DOI":"10.1148\/rycan.240269","volume":"7","author":"AL Lai","year":"2025","unstructured":"Lai AL, Velaga J, Tay KJ, Hang G, Tan YG, Yuen JSP, et al. Multiparametric MRI before and after focal therapy for prostate cancer: pearls and pitfalls for the reporting radiologist. Radio Imaging Cancer. 2025;7:e240269.","journal-title":"Radio Imaging Cancer"},{"key":"1005_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejrad.2024.111463","volume":"175","author":"AM Pausch","year":"2024","unstructured":"Pausch AM, Elsner C, Rupp NJ, Eberli D, H\u00f6tker AM. MRI-based monitoring of prostate cancer after HIFU: Inter-reader agreement and diagnostic performance of the PI-FAB score. Eur J Radio. 2024;175:111463.","journal-title":"Eur J Radio"},{"key":"1005_CR17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.euros.2024.02.012","volume":"62","author":"DG Gelikman","year":"2024","unstructured":"Gelikman DG, Kenigsberg AP, Mee Law Y, Yilmaz EC, Harmon SA, Parikh SH, et al. Evaluating diagnostic accuracy and inter-reader agreement of the prostate imaging after focal ablation scoring system. Eur Urol Open Sci. 2024;62:74\u201380.","journal-title":"Eur Urol Open Sci"},{"key":"1005_CR18","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1148\/radiol.2021202771","volume":"299","author":"C Lawhn-Heath","year":"2021","unstructured":"Lawhn-Heath C, Salavati A, Behr SC, Rowe SP, Calais J, Fendler WP, et al. Prostate-specific membrane antigen PET in prostate cancer. Radiology. 2021;299:248\u201360.","journal-title":"Radiology"},{"key":"1005_CR19","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","volume":"80","author":"L Emmett","year":"2021","unstructured":"Emmett L, Buteau J, Papa N, Moon D, Thompson J, Roberts MJ, et al. The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study. Eur Urol. 2021;80:682\u20139.","journal-title":"Eur Urol"},{"key":"1005_CR20","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.juro.2018.01.079","volume":"200","author":"E Lopci","year":"2018","unstructured":"Lopci E, Saita A, Lazzeri M, Lughezzani G, Colombo P, Buffi NM, et al. 68Ga-PSMA positron emission tomography\/computerized tomography for primary diagnosis of prostate cancer in men with contraindications to or negative multiparametric magnetic resonance imaging: a prospective observational study. J Urol. 2018;200:95\u2013103.","journal-title":"J Urol"},{"key":"1005_CR21","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.euf.2020.03.004","volume":"7","author":"E Lopci","year":"2021","unstructured":"Lopci E, Lughezzani G, Castello A, Saita A, Colombo P, Hurle R, et al. Prospective evaluation of 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography\/computed tomography in primary prostate cancer diagnosis. Eur Urol Focus. 2021;7:764\u201371.","journal-title":"Eur Urol Focus"},{"key":"1005_CR22","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1007\/s12094-020-02384-w","volume":"23","author":"E Lopci","year":"2021","unstructured":"Lopci E, Lughezzani G, Castello A, Colombo P, Casale P, Saita A, et al. PSMA-PET and micro-ultrasound potential in the diagnostic pathway of prostate cancer. Clin Transl Oncol. 2021;23:172\u20138.","journal-title":"Clin Transl Oncol"},{"key":"1005_CR23","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1053\/j.semnuclmed.2023.10.002","volume":"54","author":"M Caracciolo","year":"2024","unstructured":"Caracciolo M, Castello A, Lopci E. PSMA PET\/CT versus mpMRI for the detection of clinically significant prostate cancer: an updated overview. Semin Nucl Med. 2024;54:30\u20138.","journal-title":"Semin Nucl Med"},{"key":"1005_CR24","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.euo.2022.05.003","volume":"5","author":"E Lopci","year":"2022","unstructured":"Lopci E, Lughezzani G, Fasulo V, Lazzeri M, Stefano F, Briganti A, Emmett L, et al. EAU-EANM consensus statements on the role of prostate-specific membrane antigen positron emission tomography\/computed tomography in patients with prostate cancer and with respect to [177Lu]Lu-PSMA radioligand therapy. Eur Urol Oncol. 2022;5:530\u20136. Extended Use of PSMA PET\/CT in Candidates for Focal Therapy. Eur Urol Oncol. 2022;5:601-02.","journal-title":"Eur Urol Oncol"},{"key":"1005_CR25","first-page":"1644","volume":"63","author":"L Emmett","year":"2022","unstructured":"Emmett L, Papa N, Buteau J, Ho B, Liu V, Roberts M, et al. The PRIMARY score: using Intraprostatic 68Ga-PSMA PET\/CT patterns to optimize prostate cancer diagnosis. J Nucl Med. 2022;63:1644\u201350.","journal-title":"J Nucl Med"},{"key":"1005_CR26","doi-asserted-by":"publisher","first-page":"5036","DOI":"10.3390\/cancers14205036","volume":"14","author":"M Caracciolo","year":"2022","unstructured":"Caracciolo M, Castello A, Urso L, Borgia F, Ortolan N, Uccelli L, et al. The role of [68Ga]PSMA PET\/CT for clinical suspicion of prostate cancer in patients with or without previous negative biopsy: a systematic review. Cancers (Basel). 2022;14:5036.","journal-title":"Cancers (Basel)"},{"key":"1005_CR27","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet. 2020;395:1208\u201316. proPSMA Study Group Collaborators.","journal-title":"Lancet"},{"key":"1005_CR28","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1001\/jamaoncol.2021.3771","volume":"7","author":"TA Hope","year":"2021","unstructured":"Hope TA, Eiber M, Armstrong WR, Juarez R, Murthy V, Lawhn-Heath C, et al. Diagnostic accuracy of 68Ga-PSMA-11 PET for pelvic nodal metastasis detection prior to radical prostatectomy and pelvic lymph node dissection: a multicenter prospective phase 3 imaging trial. JAMA Oncol. 2021;7:1635\u201342.","journal-title":"JAMA Oncol"},{"key":"1005_CR29","doi-asserted-by":"publisher","first-page":"847","DOI":"10.2967\/jnumed.121.262398","volume":"63","author":"I Sonni","year":"2022","unstructured":"Sonni I, Felker ER, Lenis AT, Sisk AE, Bahri S, Allen-Auerbach M, et al. Head-to-head comparison of 68Ga-PSMA-11 PET\/CT and mpMRI with a histopathology gold standard in the detection, intraprostatic localization, and determination of local extension of primary prostate cancer: results from a prospective single-center imaging trial. J Nucl Med. 2022;63:847\u201354.","journal-title":"J Nucl Med"},{"key":"1005_CR30","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2214\/AJR.20.23912","volume":"216","author":"S Satapathy","year":"2021","unstructured":"Satapathy S, Singh H, Kumar R, Mittal BR. Diagnostic accuracy of 68Ga-PSMA PET\/CT for initial detection in patients with suspected prostate cancer: a systematic review and meta-analysis. AJR Am J Roentgenol. 2021;216:599\u2013607.","journal-title":"AJR Am J Roentgenol"},{"key":"1005_CR31","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1097\/JU.0000000000004010","volume":"212","author":"L Emmett","year":"2024","unstructured":"Emmett L, Papa N, Hope TA, Fendler W, Calais J, Burger I, et al. Beyond prostate imaging reporting and data system: combining magnetic resonance imaging prostate imaging reporting and data system and prostate-specific membrane antigen \u2013 positron emission tomography\/computed tomography primary score in a composite (P) score for more accurate diagnosis of clinically significant prostate cancer. J Urol. 2024;212:299\u2013309.","journal-title":"J Urol"},{"key":"1005_CR32","doi-asserted-by":"publisher","unstructured":"Nicoletti R, Alberti A, Gauhar V, Ciaralli E, Yee CH, Chiu P, et al. Is there a role of PSMA-PET in focal therapy planning and follow-up? Prostate Cancer Prostatic Dis. 2025 Feb. https:\/\/doi.org\/10.1038\/s41391-025-00944-1. Epub ahead of print.","DOI":"10.1038\/s41391-025-00944-1"},{"key":"1005_CR33","doi-asserted-by":"crossref","first-page":"P960","DOI":"10.2967\/jnumed.122.264988","volume":"64","author":"E Lopci","year":"2023","unstructured":"Lopci E, Lughezzani G, Fasulo V, Maffei D, Adjaye ENYD, Saita A, et al. SUV variation on PSMA PET\/CT correlates with biochemical response in patients with prostate cancer undergoing High-Intensity Focused Ultrasound (HIFU) focal therapy. J Nucl Med. 2023;64:P960.","journal-title":"J Nucl Med"},{"key":"1005_CR34","doi-asserted-by":"publisher","unstructured":"Lopci E, Lughezzani G, Fasulo V, Maffei D, Saita A, Casale P, et al. Imaging predictive biomarkers of response in patients with prostate cancer undergoing high-intensity focused ultrasound (HIFU) focal therapy. J Clin Oncol. 2024; 42:Suppl.288. https:\/\/doi.org\/10.1200\/JCO.2024.42.4_suppl.288","DOI":"10.1200\/JCO.2024.42.4_suppl.288"},{"key":"1005_CR35","doi-asserted-by":"publisher","unstructured":"Nahar B, Ajami T, Williams A, Soodana Prakash N, Khandekar A, Freitas PFS, et al. Survival outcomes and recurrence patterns following focal high-intensity focused ultrasound treatment for localized prostate cancer: insights on patient selection and lessons learned. Eur Urol Focus. 2024:S2405-456900246-3. https:\/\/doi.org\/10.1016\/j.euf.2024.11.005.","DOI":"10.1016\/j.euf.2024.11.005"},{"key":"1005_CR36","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1016\/j.eururo.2020.11.043","volume":"79","author":"RE de Feria Cardet","year":"2021","unstructured":"de Feria Cardet RE, Hofman MS, Segard T, Yim J, Williams S, Francis RJ, et al. Is Prostate-specific membrane antigen positron emission tomography\/computed tomography imaging cost-effective in prostate cancer: an analysis informed by the proPSMA Trial. Eur Urol. 2021;79:413\u20138.","journal-title":"Eur Urol"},{"key":"1005_CR37","doi-asserted-by":"publisher","first-page":"3750","DOI":"10.1007\/s00259-023-06332-y","volume":"50","author":"A Holzgreve","year":"2023","unstructured":"Holzgreve A, Unterrainer M, Calais J, Adams T, Oprea-Lager DE, Goffin K, et al. Is PSMA PET\/CT cost-effective for the primary staging in prostate cancer? First results for European countries and the USA based on the proPSMA trial. Eur J Nucl Med Mol Imaging. 2023;50:3750\u20134.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1005_CR38","doi-asserted-by":"publisher","unstructured":"Ivey MC, Deivasigamani S, Kotamarti S, Mottaghi M, Ghoreifi A, Adams ES, et al. External validation of inter-reader reliability of the Prostate Imaging after Focal Ablation (PI-FAB) scoring system following focal cryoablation and focal high-intensity focused ultrasound. Eur Radiol. 2025. https:\/\/doi.org\/10.1007\/s00330-025-11513-4. Epub ahead of print.","DOI":"10.1007\/s00330-025-11513-4"}],"container-title":["Prostate Cancer and Prostatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01005-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01005-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01005-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T21:44:47Z","timestamp":1786657487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41391-025-01005-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,30]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1005"],"URL":"https:\/\/doi.org\/10.1038\/s41391-025-01005-3","relation":{},"ISSN":["1365-7852","1476-5608"],"issn-type":[{"value":"1365-7852","type":"print"},{"value":"1476-5608","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,30]]},"assertion":[{"value":"7 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Davide Maffei\u2019s as affiliations should be 2 and 3, not 4 and 5.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"EL reports receiving grant support from the Italian Ministry of Health (Ministero della Salute). The remaining authors have nothing to disclose.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}